Close Menu

NEW YORK – Inflammatix on Friday announced that it had raised $32 million in Series C financing to advance its rapid HostDx tests through commercial launch in Europe and submission for clearance to the US Food and Drug Administration in 2021.

The funding round included participation from existing investors Khosla Ventures, Northpond Ventures, and Think.Health Ventures, and new investors that included Grey Sky Venture Partners.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.